Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Quantum Phar. LSE:QP. London Ordinary Share GB00BRTL8Q42 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 84.2374p 0 05:00:01
Bid Price Offer Price High Price Low Price Open Price
84.00p 84.75p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 88.77 -10.85 -16.90 142.5

Quantum Phar. (QP.) Latest News

Real-Time news about Quantum Phar. (London Stock Exchange): 0 recent articles
More Quantum Phar. News
Quantum Phar. Takeover Rumours

Quantum Phar. (QP.) Share Charts

1 Year Quantum Phar. Chart

1 Year Quantum Phar. Chart

1 Month Quantum Phar. Chart

1 Month Quantum Phar. Chart

Intraday Quantum Phar. Chart

Intraday Quantum Phar. Chart

Quantum Phar. (QP.) Discussions and Chat

Quantum Phar. Forums and Chat

Date Time Title Posts
31/10/201708:46Quantum Pharma PLC - Charts included.632
12/7/201608:05Quantum Pharma PLC904

Add a New Thread

Quantum Phar. (QP.) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Quantum Phar. trades in real-time

Quantum Phar. (QP.) Top Chat Posts

mfhmfh: Let's hope this helps CLIN's and QP.'s share price: Peel Hunt today upgrades its investment rating on Clinigen Group (LON:CLIN) to buy (from add) and raised its price target to 1350p (from 1200p).
glasshalfull: Well CLIN share price reacting adversely to the offer. Down over 4% as I type. Thought it would have been welcomed by CLIN shareholders as earnings accretive per the update I posted from Peel Hunt previously. Value of cash & shares offer now = 80p combined following the fall. I cashed up at the open. Best of luck to holders. Kind regards, GHF
glasshalfull: See my recent post 585...Peel Hunt weren't far out! They speculated 84.5p vs 82p announced this morning. 45% of the consideration in cash & as earnings accretive to CLIN I'm hopefully this may result in a boost to the CLIN share price. Irrespective, 23% premium to yesterdays share price isn't too shabby. Kind regards, GHF
rosejs2: Daclam. Management hopefully will be looking after the interests of ALL shareholders...The Instituions will want a more than adequate return for the risk they took both as shareholders and as members of the Lifeboat fundraising.. Management will be well rewarded..Note the words 'On a Change of Control' From the November 2016 RNS re option grant: "The LTIP options have been granted to key members of the senior executive team. The options shall vest and become exercisable at an exercise price of 30 pence, either on the mid-market closing share price being greater than 140p for an average of 90 days or on a change of control." CLinigens takeover stratefy is in full swing.with friendly associates consistantly selling small and not so small blocks of QP shares.. Forms 8.3 and 8.5 give insight into their share dealings... Driving down the price is the obvious way forward whilst driving out weak holders.. I suspect the very positive share price of Clinigen will allow them to win the day..It has risen every day for the last week.. My view for what it is worth .. 80p or there abouts will win the day.
duncan doughnut: Well I'm home tonight to see my CLIN are in talks to buy my QP. and both shares are up :-] That's a win/win for me. CLIN are trading on a much higher rating that QP. so they can pay a good price and it would still be earnings enhancing. CLIN are making their move now before the growth here really starts to show. I think the new board will hold out for a good price as they haven't even had time to stamp their mark and the company would be taken away from them just as they were going to get the credit. CLIN are 10 times the size of QP., easily in their scope to buy. Bid has to be in 3 fig share price I'd say, if it's to go through. Perhaps after the interims investors will get a better idea of the value here and appreciate what a bid price would need to be.
rivaldo: New interview with the CEO: Http:// Extracts: "Quantum Pharma 'fundamentally successful' in simplifying strategy, says chief executive" "Quantum Pharma’s new business model has been hailed as a “fundamental success” by chief executive Chris Rigg, three months after he closed the company’s struggling NuPharm division." "Mr Rigg said that Quantum’s effort to focus its business is now paying off. Speaking to The Journal Mr Rigg said: “The position that the business brought to float was the ability to convert unlicensed medicines to licensed. It then acquired NuPharm. “It was the business I closed, and it was a business that was failing. It was acquired for the right strategic intent but it was failing. “Part of what I have done is to focus and simplify the business. “When you license a product we bring it to market at a lower price than the unlicensed medicine. We can do that as we get a higher market share and manufacture it in bulk. “The aim is to drive into the future the benefits of the license programme to lower prices in the NHS.” Under the renewed strategy Quantum is focusing on its core business. This is largely the supply of unlicensed medications – known as specials – and the creation of licensed products through its Colonis arm. With its network of pharmacies across the UK, Quantum is a market leader in supplying adapted medicines to the market. This process can involve making liquid versions of pills or changing the flavour of medication. One of the key areas for growth for the firm is Colonis and its licensing division. Once a drug successfully attains a UK license the business involves becomes the only one able to distribute the medication to pharmacies. This gives its a major market advantage. As part of the new model Mr Rigg has appointed new management teams to oversee its divisions, including Colonis. “From a control perspective it allows you to focus,” said Rigg. “You can change and make people accountable.” Despite writing off £13.7m as a result of the NuPharm sale, Mr Rigg said investors reacted well to the renewed focus on its core business. The company’s share price reflected his optimism, and following the closure of NuPharm, Quantum’s share price soared from 43p to 60p over seven days. The price has since levelled off and at the time of writing sits at 55.25p."
rivaldo: Just been tipped: Http:// "In fact, here are two stocks which appear to be cheap based on their future prospects. But does that mean they are worth buying today? Impressive update Reporting on Monday was service-led niche pharmaceutical developer, Quantum Pharma(LSE: QP). The company announced the disposal of Total Medication Management Services, which is a homecare dispensary and delivery business which trades as Biodose Services. The disposal is another significant step in the transition of the business as it seeks to focus on its core Specials and Niche Pharmaceuticals divisions. The initial cash consideration on disposal will be £1.75m, with a maximum additional contingent consideration of £0.2m. The sale of the division improves Quantum Pharma's EBITDA (earnings before interest, tax, depreciation and amortisation) margin by eliminating low-margin turnover. In addition, the company's remaining divisions have traded ahead of expectations in the early months of the year. The company expects this to offset the majority of the disposed contribution from Biodose Services in the current year. Looking ahead, Quantum Pharma is expected to report a rise in its bottom line of 31% in the next financial year. Even after today's 3%+ rise in its share price, this leaves the business trading on a price-to-earnings growth (PEG) ratio of just 0.4. This suggests its capital growth potential is high, which means it may be worth buying for the long term."
r ball: I'm always wary of roadshows. Why bother if you don't want to raise money. It's managements job to run the business not pander to existing investors or the share price.
werewolfie: I asked the same question on LSE website and someone responded with a very interesting post - QP's share price has a lot of ground to make up... But is making great progress due to the following:- (1) Appointment of new CFO Chris Rigg currently acting CEO (2) Appointment of a new CEO (details awaited) (3) Removal of Andrew Scaife (4) A validated pipeline of new products being approved and launched substantially more effectively than previous. (5) Uniqueness of Bio Dose / Bio Dose connect. (6) On track to meet target earnings and EBITDA for 16/17 (7) The appointment of Lisa Brigham as its corporate communications manager,This is real evidence that QP is serious about improving its Marketing and Wider Communications ability to improve both Sales, Margin and importantly Communications with shareholders / stakeholders... Including Institutional shareholders.. (8) The addition of the Slater Investments to the Major Shareholder List. There appears also to be a number of large trades going through the market over the past week... It might be Mr Scaife reducing his not insubstantial holding... But it appears at least to me either other Major shareholders are topping up ( an RNS will confirm this in the near future) or a predator is stake building.. There are a limited number of free Float shares and if institutions are topping up then we can expect further rises in the value of QP shares in the run up to interim results.. The appointment of the new CEO should add further impetus to the share price... Product launches should remain a secret until final approval and launch plans confirmed in order to stop competitors either copying or attempting to derail QP's launch plans ... Hence no sight of them on the Company website.. QP has previously quoted a total Pipeline of X products (audited externally) and an estimated overall value to the company... No doubt that this is being added to continuously. This is a unique company and with the changes detailed above and a set of unique products and services .. We have a real opportunity to retrace previous high's in its share price,
rosejs2: Buffy on the 19th Jan Was aware of the following... Quantum Pharma said its directors report group adjusted EBITDA for the year to Jan. 31 is expected to be about GBP12.7m, versus market consensus of GBP13.4m. "Overall the Group has progressed significantly in FY 2016," it said in a statement. "However, the Niche Pharmaceutical division has experienced delays in its product pipeline. As a result of this, the Board now expects more moderate double digit revenue and EBITDA growth for FY 2017." This to my knowledge has NOT been downgraded further... What is becoming apparent is the unusual pattern in share trading..Small share trades including trades of 25, 27, 37 shares... Lots of AT trades of 5000.. I am no expert at all on interpreting what I might regard as share manipulation... all legal of course.. but I would not be surprised to find that somebody or some organisation are not building or manipulating the share price for their advantage.. including a possible takeover at a less than generous price to existing shareholders.. The Weakness in QP I believe is a number of its senior team.. Don't rate the Chairman.. The Invisible Man - who should be replaced.. Don't Rate QP's NOMAD zeus... Hopeless in supporting the share price or selling the QP growth story.. Don't rate the Investor relations Dept - Hopeless Don't rate the PR advisors to QP... Change them immediately Sorry about the rant.. but QP has a number of real opportunities to create shareholder value...But changes at the top and with its advisers are needed.. Perhaps we might even see a return to Private ownership for QP.. nothing should be ruled out..
Quantum Phar. share price data is direct from the London Stock Exchange
Your Recent History
Quantum Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181219 10:30:51